Successful continual intratympanic steroid injection therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis

Koichiro Wasano, Shuta Tomisato, Sayuri Yamamoto, Noriomi Suzuki, Taiji Kawasaki, Kaoru Ogawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To report the treatment efficacy of continual intratympanic steroid injection (ITSI) therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis. Patient: A 49-year-old female diagnosed with relapsing polychondritis at the age of 45 years and who had been treated with corticosteroids and immunosuppressants developed sensorineural hearing loss in the left ear. Intervention: Her unilateral hearing loss did not recover despite receiving one cyclophosphamide pulse treatment, one methylprednisolone pulse treatment, and weekly leukapheresis. Thus, we decided to initiate weekly ITSI therapy. Main outcome measure: Pure tone audiometry. Results: A week after the first ITSI treatment, the patient's hearing improved. We continued ITSI therapy and attempted to extend the interval between treatments, but her hearing worsened when ITSI therapy was delivered at 2- to 3-week intervals. Thus, we returned ITSI therapy to once per week for 21 months (total of 71 treatments). She experienced no adverse events, like tympanic perforation, and 1 year after terminating the therapy, her hearing remained stable and did not worsen. Conclusions: Continual, weekly ITSI therapy was effective in treating sensorineural hearing loss accompanied by relapsing polychondritis. ITSI therapy may be a promising treatment option for sensorineural hearing loss caused by autoimmune disease.

Original languageEnglish
JournalAuris Nasus Larynx
DOIs
Publication statusAccepted/In press - 2016 May 12

Fingerprint

Relapsing Polychondritis
Sensorineural Hearing Loss
Steroids
Therapeutics
Hearing
Intratympanic Injection
Unilateral Hearing Loss
Pure-Tone Audiometry
Leukapheresis
Methylprednisolone
Immunosuppressive Agents

Keywords

  • Autoimmune inner ear disease
  • Inner ear
  • Intratympanic steroid injection
  • Relapsing polychondritis

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Successful continual intratympanic steroid injection therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis. / Wasano, Koichiro; Tomisato, Shuta; Yamamoto, Sayuri; Suzuki, Noriomi; Kawasaki, Taiji; Ogawa, Kaoru.

In: Auris Nasus Larynx, 12.05.2016.

Research output: Contribution to journalArticle

@article{685935b2633247098cf682a52d650ba6,
title = "Successful continual intratympanic steroid injection therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis",
abstract = "Objective: To report the treatment efficacy of continual intratympanic steroid injection (ITSI) therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis. Patient: A 49-year-old female diagnosed with relapsing polychondritis at the age of 45 years and who had been treated with corticosteroids and immunosuppressants developed sensorineural hearing loss in the left ear. Intervention: Her unilateral hearing loss did not recover despite receiving one cyclophosphamide pulse treatment, one methylprednisolone pulse treatment, and weekly leukapheresis. Thus, we decided to initiate weekly ITSI therapy. Main outcome measure: Pure tone audiometry. Results: A week after the first ITSI treatment, the patient's hearing improved. We continued ITSI therapy and attempted to extend the interval between treatments, but her hearing worsened when ITSI therapy was delivered at 2- to 3-week intervals. Thus, we returned ITSI therapy to once per week for 21 months (total of 71 treatments). She experienced no adverse events, like tympanic perforation, and 1 year after terminating the therapy, her hearing remained stable and did not worsen. Conclusions: Continual, weekly ITSI therapy was effective in treating sensorineural hearing loss accompanied by relapsing polychondritis. ITSI therapy may be a promising treatment option for sensorineural hearing loss caused by autoimmune disease.",
keywords = "Autoimmune inner ear disease, Inner ear, Intratympanic steroid injection, Relapsing polychondritis",
author = "Koichiro Wasano and Shuta Tomisato and Sayuri Yamamoto and Noriomi Suzuki and Taiji Kawasaki and Kaoru Ogawa",
year = "2016",
month = "5",
day = "12",
doi = "10.1016/j.anl.2016.07.019",
language = "English",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Successful continual intratympanic steroid injection therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis

AU - Wasano, Koichiro

AU - Tomisato, Shuta

AU - Yamamoto, Sayuri

AU - Suzuki, Noriomi

AU - Kawasaki, Taiji

AU - Ogawa, Kaoru

PY - 2016/5/12

Y1 - 2016/5/12

N2 - Objective: To report the treatment efficacy of continual intratympanic steroid injection (ITSI) therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis. Patient: A 49-year-old female diagnosed with relapsing polychondritis at the age of 45 years and who had been treated with corticosteroids and immunosuppressants developed sensorineural hearing loss in the left ear. Intervention: Her unilateral hearing loss did not recover despite receiving one cyclophosphamide pulse treatment, one methylprednisolone pulse treatment, and weekly leukapheresis. Thus, we decided to initiate weekly ITSI therapy. Main outcome measure: Pure tone audiometry. Results: A week after the first ITSI treatment, the patient's hearing improved. We continued ITSI therapy and attempted to extend the interval between treatments, but her hearing worsened when ITSI therapy was delivered at 2- to 3-week intervals. Thus, we returned ITSI therapy to once per week for 21 months (total of 71 treatments). She experienced no adverse events, like tympanic perforation, and 1 year after terminating the therapy, her hearing remained stable and did not worsen. Conclusions: Continual, weekly ITSI therapy was effective in treating sensorineural hearing loss accompanied by relapsing polychondritis. ITSI therapy may be a promising treatment option for sensorineural hearing loss caused by autoimmune disease.

AB - Objective: To report the treatment efficacy of continual intratympanic steroid injection (ITSI) therapy in a patient with refractory sensorineural hearing loss accompanied by relapsing polychondritis. Patient: A 49-year-old female diagnosed with relapsing polychondritis at the age of 45 years and who had been treated with corticosteroids and immunosuppressants developed sensorineural hearing loss in the left ear. Intervention: Her unilateral hearing loss did not recover despite receiving one cyclophosphamide pulse treatment, one methylprednisolone pulse treatment, and weekly leukapheresis. Thus, we decided to initiate weekly ITSI therapy. Main outcome measure: Pure tone audiometry. Results: A week after the first ITSI treatment, the patient's hearing improved. We continued ITSI therapy and attempted to extend the interval between treatments, but her hearing worsened when ITSI therapy was delivered at 2- to 3-week intervals. Thus, we returned ITSI therapy to once per week for 21 months (total of 71 treatments). She experienced no adverse events, like tympanic perforation, and 1 year after terminating the therapy, her hearing remained stable and did not worsen. Conclusions: Continual, weekly ITSI therapy was effective in treating sensorineural hearing loss accompanied by relapsing polychondritis. ITSI therapy may be a promising treatment option for sensorineural hearing loss caused by autoimmune disease.

KW - Autoimmune inner ear disease

KW - Inner ear

KW - Intratympanic steroid injection

KW - Relapsing polychondritis

UR - http://www.scopus.com/inward/record.url?scp=84995900454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995900454&partnerID=8YFLogxK

U2 - 10.1016/j.anl.2016.07.019

DO - 10.1016/j.anl.2016.07.019

M3 - Article

C2 - 27552828

AN - SCOPUS:84995900454

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

ER -